Unlike several other HER2-driven cancer types that are primarily due to HER2 copy number gain/amplifications, approximately 90% of HER2 alterations in NSCLC are exon 20 insertions that account for 1.5–2% of all NSCLCs [2]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.